Nanoscope Therapeutics Inc.
Brett Kiedaisch is an experienced professional in analytical development and quality control, currently serving as Associate Director at Nanoscope Therapeutics Inc. since April 2024. Previously, Brett held positions including Associate Director/Director at Senti Biosciences, where responsibilities included leading the Analytical Development group for CAR-NK programs, developing testing strategies, and building a high-functioning team. Additional experience includes roles at Stanford University School of Medicine, Smith & Nephew, and Healthpoint Biotherapeutics, focusing on the development and quality control of cell and gene therapies. Brett's academic background includes a Master’s degree in Biology with a focus on Plant Cell Wall Development and a Bachelor’s degree in Cell & Molecular Biology, both from Texas Tech University.
Previous companies
This person is not in any teams
This person is not in any offices
Nanoscope Therapeutics Inc.
1 followers
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells. Update: June, 2021: Nanoscope Therapeutics Announces FDA Approval of IND for Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa